Table 4.

Baseline demographics and laboratory characteristics of participants in the anakinra trial

	Anakinra (n=35)	Placebo (n=34)
Age (years)
Mean (SD)	26·6 (5·3)	25·0 (4·5)
Median (range)	27 (18–34)	25 (18–34)
Men	26 (74%)	22 (65%)
White*	32 (97%)	33 (100%)
Duration from diagnosis to treatment start (days)
Mean (SD)	64·2 (18·0)	59·8 (17·1)
Median (range)	65·0 (29–95)	62·5 (32–85)
Weight (kg)†	72·0 (10·9)	72·0 (12·7)
Body-mass index (kg/m2)‡	22·9 (2·7)	22·8 (2·8)
Area under the curve for C peptide (nmol/L)	0·62 (0·26)	0·73 (0·37)
Glycated haemoglobin (%)§	7·63 (1·43)	7·30 (1·15)
Fasting plasma glucose (mmol/L)	6·9 (1·9)	7·3 (1·8)
Area under the curve for glucose (mmol/L)	10·4 (2·3)	10·9 (2·4)
Total daily insulin dose (units/kg per day)¶	0·42 (0·34)	0·38 (0·35)
Interleukin-6 (ng/L)∥	2·32 (1·38)	2·53 (15·6)
Interleukin-1 receptor antagonist (μg/L)∥	31·1 (125·0)	0·31 (0·20)
C-reactive protein (mg/L)**	1·47 (3·04)	1·43 (2·31)

Data are number (%) or mean (SD) unless otherwise specified.

^*Excludes two participants in the anakinra group and one in the placebo group who did not report ethnic origin.

^†Data missing for two patients in the anakinra group and two in the placebo group.

^‡Data missing for three patients in the anakinra group and two in the placebo group.

^§Data missing for three patients in the anakinra group.

^¶Data missing for one patient in the anakinra group and three in the placebo group.

^∥Data missing for one patient in the anakinra group.

^**Data missing for one patient in the placebo group.